Products
Crucell vaccines have an excellent safety record and were distributed globally in more than 100 countries in 2009. In the following sections we focus on our range of marketed products, many of which offer unique advantages to the people who benefit from them.
Vaccines play a pivotal role in protecting against diseases and contribute significantly to an improvement in global health.
Products
Our marketed vaccines currently combat 12 major infectious diseases. In 2009 we distributed more than 115 million vaccine doses in over 100 countries throughout the world. Our product portfolio consists of three distinct focus areas:
- Paediatric
- Travel & endemic
- Respiratory
Quinvaxem®
Quinvaxem® is the only fully liquid pentavalent DTwP-HepB-Hib vaccine that is free from the preservative thiomersal. It is an ideal solution for infants and protects against five potentially deadly childhood diseases: diphtheria, tetanus, pertussis, Haemophilus influenzae type b disease and hepatitis B. In its fifth year in the Extended Programme for Immunization (EPI), over 130 million doses of Quinvaxem® have been delivered to more than 50 countries. In August 2009, supranational organizations renewed a long-term arrangement with Crucell for the supply of $300 million worth of Quinvaxem® for the period 2010-2012. This figure is projected to grow further over the three year period. Today Quinvaxem® has a market share of over 50%.
Hepavax-Gene®
Hepavax-Gene® is a prophylactic recombinant vaccine against hepatitis B virus infection, providing long-term protection. With a track record of more than 500 million doses administered worldwide, it is also one of the established WHO pre-qualified vaccines.
MoRu-Viraten®
MoRu-Viraten® is a safe, well-tolerated and effective vaccine for protection against measles and rubella in children, adolescents and adults. MoRu-Viraten® is free of egg proteins and antibiotics, posing no risk to children with allergies to these substances. The vaccine has been marketed since 1986 and is on the WHO list of vaccines for purchase by UN agencies.
Epaxal® and Epaxal® Junior
Epaxal® is the only aluminum-free hepatitis A vaccine on the market. The absence of aluminum reduces the pain when injected, making it particularly well-suited to the paediatric market. Epaxal® induces protective antibody levels within 10 days of primary vaccination and provides seroprotection for at least 20 years following the second (booster) dose. Its excellent efficacy and safety have been documented in many clinical trials and it can be fitted into the regular immunization schedule for babies. Epaxal® is licensed in more than 40 countries worldwide. Epaxal® Junior is a low dosage vaccine for the paediatric market with superior tolerability.
Vivotif®
Vivotif® is a live attenuated oral vaccine for the prevention of typhoid fever. It is the only oral vaccine indicated for use against Salmonella typhi, the most prevalent of the enteric fever-causing bacteria. Protective efficacy has been proven in several large-scale field trials and it has an excellent track record for safety, having been on the market for more than 20 years. It is currently licensed in over 30 countries, including the USA. Results suggest that Vivotif® may be unique in also protecting against S. paratyphi, another common cause of enteric fever.
Dukoral®
Dukoral® is a liquid oral vaccine which stimulates the immune response in the intestine to provide 85% protection against diarrhea caused by cholera. It has also shown documented protection against traveler’s diarrhea caused by e-coli. Dukoral® was first licensed in 1992 and is now licensed in over 60 countries. It is presently the only internationally licensed oral cholera vaccine. To date, more than 10 million doses of Dukoral® have been supplied and it enjoys an excellent safety record.
Inflexal® V
Inflexal® V is a virosomal adjuvanted vaccine against influenza, based upon the virosome technology developed and patented by Crucell. It is the only adjuvanted flu vaccine licensed for all age groups (from six months). The vaccine’s antigen composition follows yearly WHO recommendations. Inflexal® V was originally introduced in 1997, is registered in 43 countries and has extensive market experience, with more than 49 million doses confirming its safety profile. The tolerability of Inflexal® V is excellent due to its biocompatibility and purity.
We also distribute a variety of other products, such as Gardasil® (Merck) and Prolastin® (Talecris).